TR201904662T4 - Anti-fxı antikorları ve kullanma yöntemleri. - Google Patents

Anti-fxı antikorları ve kullanma yöntemleri. Download PDF

Info

Publication number
TR201904662T4
TR201904662T4 TR2019/04662T TR201904662T TR201904662T4 TR 201904662 T4 TR201904662 T4 TR 201904662T4 TR 2019/04662 T TR2019/04662 T TR 2019/04662T TR 201904662 T TR201904662 T TR 201904662T TR 201904662 T4 TR201904662 T4 TR 201904662T4
Authority
TR
Turkey
Prior art keywords
fxi
monoclonal antibodies
antibodies
patent application
fxiia
Prior art date
Application number
TR2019/04662T
Other languages
English (en)
Inventor
Gruber Andras
I Tucker Erik
Gailani David
Original Assignee
Gruber Andras
Gailani David
I Tucker Erik
Univ Oregon Health & Science
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruber Andras, Gailani David, I Tucker Erik, Univ Oregon Health & Science, Univ Vanderbilt filed Critical Gruber Andras
Publication of TR201904662T4 publication Critical patent/TR201904662T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bu patent başvurusunda, faktör XI (fXI) için spesifik olan ve faktör XIIa (fXIIa) ile fXI aktivasyonunu önleyen monoklonal antikorlar açıklanmaktadır. Bu monoklonal antikorlar, test edilen tüm memeli türlerini bağlama kabiliyeti bulunan evrensel fXI antikorlarıdırlar. Anti-fXI monoklonal antikorları, memeli plazmalarında pıhtılaşma süresini uzatırlar. Ayrıca, bu patent başvurusunda açıklanan fXI monoklonal antikorlarının uygulanması, trombozun hayvan modellerinde, trombozun hemostazı değiştirmeden inhibe edilmesiyle sonuçlanmaktadır. Dolayısıyla, bu patent başvurusunda, fXI için spesifik olan ve fXIIa ile fXI aktivasyonunu bloke eden monoklonal antikorlar, bu tür antikorları içeren bileşimler ve immünokonjügatlar ve ayrıca, bunları kullanma yöntemleri açıklanmaktadır.
TR2019/04662T 2008-12-18 2009-12-18 Anti-fxı antikorları ve kullanma yöntemleri. TR201904662T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13859008P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
TR201904662T4 true TR201904662T4 (tr) 2019-05-21

Family

ID=42317079

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04662T TR201904662T4 (tr) 2008-12-18 2009-12-18 Anti-fxı antikorları ve kullanma yöntemleri.

Country Status (15)

Country Link
US (3) US8388959B2 (tr)
EP (1) EP2373691B1 (tr)
AU (1) AU2009335643B2 (tr)
CA (1) CA2747519C (tr)
CY (1) CY1121562T1 (tr)
DK (1) DK2373691T3 (tr)
ES (1) ES2720594T3 (tr)
HR (1) HRP20190605T1 (tr)
HU (1) HUE042940T2 (tr)
LT (1) LT2373691T (tr)
PL (1) PL2373691T3 (tr)
PT (1) PT2373691T (tr)
SI (1) SI2373691T1 (tr)
TR (1) TR201904662T4 (tr)
WO (1) WO2010080623A2 (tr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
LT2373691T (lt) * 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
CN102600471A (zh) * 2012-02-15 2012-07-25 中国人民解放军军事医学科学院微生物流行病研究所 一种败血症治疗的靶点
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
JP7068160B2 (ja) 2015-07-21 2022-05-16 武田薬品工業株式会社 第ＸＩＩａ因子のモノクローナル抗体阻害剤
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
RU2021129189A (ru) * 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
US11059905B2 (en) 2016-03-23 2021-07-13 Prothix B.V. Monoclonal antibodies against the active site of factor XI and uses thereof
US11136370B2 (en) * 2016-05-13 2021-10-05 The Scripps Research Institute Compositions and methods for thrombin generation assay
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
MY201852A (en) 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies
EP4413996A3 (en) 2016-09-20 2024-10-23 Aronora, Inc. Novel antibodies against factor xi and uses thereof
BR112019012667A2 (pt) * 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
WO2020029179A1 (en) * 2018-08-09 2020-02-13 Shanghai Benemae Pharmaceutical Corporation Anti-factor xi antibodies
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
EP3713965A1 (en) 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP7509787B2 (ja) * 2019-01-21 2024-07-02 アロノラ・インコーポレイテッド 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用
WO2020211674A1 (zh) 2019-04-16 2020-10-22 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
KR20230034361A (ko) * 2020-07-02 2023-03-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도
KR20230035079A (ko) * 2020-07-03 2023-03-10 수조우 알파맵 씨오., 엘티디. 응고인자 xi(fxi) 결합 단백질
WO2023070097A2 (en) 2021-10-22 2023-04-27 Regeneron Pharmaceuticals, Inc. Factor xi a2 domain-binding antibodies and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
WO2009046274A1 (en) * 2007-10-03 2009-04-09 The University Of Vermont And State Agriculture College Methods of detection of factor xia and tissue factor
ES2566963T3 (es) * 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
LT2373691T (lt) * 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
JP6005134B2 (ja) 2011-04-21 2016-10-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ フルオロアルキル置換ピラゾロピリジンおよびその使用
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
PH12014500460A1 (en) 2011-09-02 2014-04-14 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor

Also Published As

Publication number Publication date
CA2747519C (en) 2019-04-02
DK2373691T3 (en) 2019-04-15
US8388959B2 (en) 2013-03-05
US20130129745A1 (en) 2013-05-23
EP2373691A4 (en) 2012-10-31
US20110250207A1 (en) 2011-10-13
CY1121562T1 (el) 2020-05-29
SI2373691T1 (sl) 2019-05-31
AU2009335643A1 (en) 2011-07-07
HRP20190605T1 (hr) 2019-05-31
HUE042940T2 (hu) 2019-07-29
US20150093395A1 (en) 2015-04-02
US9637550B2 (en) 2017-05-02
CA2747519A1 (en) 2010-07-15
WO2010080623A3 (en) 2010-11-18
EP2373691B1 (en) 2019-01-23
PL2373691T3 (pl) 2019-07-31
EP2373691A2 (en) 2011-10-12
ES2720594T3 (es) 2019-07-23
US8940883B2 (en) 2015-01-27
WO2010080623A2 (en) 2010-07-15
PT2373691T (pt) 2019-05-08
LT2373691T (lt) 2019-05-27
AU2009335643B2 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
WO2010080623A3 (en) Anti-fxi antibodies and methods of use
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
PH12019501126A1 (en) Bispecific antibodies binding to coagulation factor ix and ciagulation factor x
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MX2018005512A (es) Agentes de union de esclerostina.
NO20084878L (no) Humanisert C-kit antistoff
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
DOP2012000089A (es) Anticuerpos monoclonales
CL2008003561A1 (es) Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
EP3716757A4 (en) WEED CONTROL COMPOSITIONS, KITS AND PROCEDURES
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
EA201490823A1 (ru) Агенты, реверсирующие действие антикоагулянтов
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов